SE Therapeutics provides a protein‑domain platform that uses self‑entering CRISPR‑Cas proteins and single‑chain antibodies to simplify and scale the manufacturing of cell and gene therapies. By leveraging microbial toxin‑derived domains, the technology reduces purification steps, improves yield, and enables biotech and pharma companies to produce rare‑disease treatments at commercial scale.
Funding
Funding not disclosed
Founders
Product
Problem
Cell and gene therapies for rare central nervous system and acute autoimmune diseases are hindered by complex manufacturing workflows and poor scalability, making large‑scale production economically infeasible. This limits the availability of treatments for hundreds of rare, often lethal diseases.
Solution
SE Therapeutics leverages protein domains naturally selected by microbes to penetrate human cells, creating a platform that streamlines the production of cell and gene therapeutics. By employing self‑entering CRISPR‑Cas proteins and single‑chain antibodies, the technology bypasses traditional delivery barriers and simplifies manufacturing steps. The approach enables higher yields and more consistent product quality, reducing cost and time to scale. Consequently, therapies that were previously impractical to produce at commercial scale become viable for clinical development and patient access.
Target Audience
Primary customers are biotech and pharmaceutical companies developing cell‑based or gene‑editing therapies for rare neurological and autoimmune indications, as well as contract manufacturing organizations seeking scalable production solutions.
Features
- Self‑entering CRISPR‑Cas proteins that facilitate intracellular delivery without auxiliary vectors
- Self‑entering single‑chain antibodies for targeted modulation of cellular pathways
- Modular protein‑domain platform derived from microbial toxins, allowing rapid adaptation to different therapeutic cargos
- Simplified manufacturing workflow that reduces the number of purification and formulation steps
- Scalable production process compatible with existing biomanufacturing infrastructure
- Enhanced payload stability and activity through native protein‑domain engineering